Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270123 | 0.89 | EGLN1 (0.55) | NPC1RAB9AEGLN1SMN1; SMN2MEN1 | |
| SCHEMBL1269290 | 0.84 | EGLN1 (0.53) | EGLN1NAMPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1270486 | 0.81 | EGLN1 (0.48) | NPC1RAB9AEGLN1SMN1; SMN2MEN1 | |
| SCHEMBL3623430 | 0.77 | EGLN1 (0.52) | RAB9AEGLN1SMN1; SMN2ERCC1FEN1 | |
| SCHEMBL1269072 | 0.77 | EGLN1 (0.54) | RAB9AEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL27790182 | 0.77 | EGLN1 (0.54) | RAB9AEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL1270465 | 0.76 | EGLN1 (0.78) | EGLN1 | |
| SCHEMBL1270309 | 0.76 | EGLN1 (0.61) | EGLN1ALDH1A1HPGDPOLB | |
| SCHEMBL1269585 | 0.75 | EGLN1 (0.54) | NPC1RAB9AEGLN1SMN1; SMN2MEN1 | |
| SCHEMBL5022605 | 0.73 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | claimed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | claimed |
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | NPC1 882/4885RAB9A 2270/4885EGLN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.